Martin Everett is CSO of Aurobac Therapeutics (Lyon, France), which is developing precision medicines for severe AMR bacterial infections. He has a PhD in molecular microbiology from the University of Bristol and was a postdoctoral researcher in the Antimicrobial Research Group at the University of Birmingham before joining GSK. At GSK he worked on TB drug discovery and led a group in the Molecular Screening department before joining the Natural Product discovery spin-out MerLion Pharmaceuticals (Singapore) as Head of Research. In 2012, Martin joined Antabio SAS (Toulouse) where he became CSO leading Antabio’s AMR drug development programs before moving to Aurobac in 2023. He currently lives in Harrogate (UK).